Biodexa Pharmaceuticals Plc ADR Dossier - Source-backed chat

Biodexa Pharmaceuticals Plc ADR

BDRXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.12

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.63Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $651K

Enterprise Value −$5.7M

Shares Outstanding 1M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company that has successfully transitioned from a drug delivery platform to a therapeutics-focused developer of treatments for gastrointestinal cancers and rare diseases. Its lead asset, eRapa, is currently in a registrational Phase 3 trial (Serenta) for Familial Adenomatous Polyposis (FAP), supported by substantial grants from CPRIT. The company has also expanded its pipeline by licensing MTX240, a novel molecular glue for GIST, from Otsuka. However, Biodexa remains a pre-revenue entity with a high cash burn rate. With its current cash runway extending only into Q3 2026, the company faces significant near-term financing risks and potential dilution, making a 'Hold' recommendation appropriate until further funding is secured or clinical milestones are achieved.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.06

Mean target$10.06

High · most bullish analyst$10.06

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company fails to secure additional financing by Q3 2026, leading to severe liquidity constraints. Clinical trials face delays, or the company is forced to execute highly dilutive equity offerings, severely depressing the share price and risking Nasdaq delisting.

Base CaseCentral scenario

The Phase 3 Serenta trial for eRapa continues steady enrollment, and the company successfully initiates the Phase 1b/2a trial for MTX240 by late 2026. Biodexa manages to extend its cash runway beyond Q3 2026 through strategic non-dilutive grants, partnerships, or controlled drawdowns from its $35 million ELOC, avoiding severe equity dilution.

Bull CaseUpside scenario

Successful clinical execution of the Phase 3 Serenta trial for eRapa in FAP and timely Phase 1b/2a initiation for MTX240 in GIST, unlocking non-dilutive CPRIT grant milestones and driving significant valuation re-rating toward the analyst target of $7.00.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Late-stage clinical asset (eRapa) in Phase 3 for FAP, a rare disease with no approved drug therapies.
Strong financial backing for eRapa via CPRIT grants, covering a substantial portion of trial costs.
Promising pipeline expansion with MTX240, a novel molecular glue licensed from Otsuka targeting GIST.
Orphan Drug Designation for eRapa in both the US and EU, providing up to 10 years of market exclusivity upon approval.

Key Investment Risks

Critical near-term funding risk with cash runway only extending into Q3 2026.
High risk of shareholder dilution from future equity offerings or ELOC drawdowns.
Clinical trial execution risks, including slow patient recruitment for the Serenta trial.
Historical share price volatility and risk of failing to maintain Nasdaq listing compliance.

Thesis Invalidation Triggers

Inability to secure additional capital or strategic partnerships before the end of Q3 2026.
Clinical hold or negative safety/efficacy signals in the eRapa Phase 3 trial.
Delays in IND filing or manufacturing of clinical supplies for MTX240.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.